<?xml version="1.0" encoding="UTF-8"?>
<p id="Par80">Three drugs (zanamivir, oseltamivir, and peramivir) are structurally related and inhibit neuraminidases on the cell surface membranes of both influenza A and B viruses and are approved by the US Food and Drug Administration [
 <xref ref-type="bibr" rid="CR5">5</xref>]. Both amantadine and rimantadine can target the IV M2 protein, to inhibit the proton channel [
 <xref ref-type="bibr" rid="CR6">6</xref>, 
 <xref ref-type="bibr" rid="CR7">7</xref>]. Baloxavir marboxil is a selective drug that inhibits the IV cap-dependent endonuclease, thus preventing IV proliferation by inhibiting the mRNA initiation reaction [
 <xref ref-type="bibr" rid="CR8">8</xref>]. However, resistance to anti-IV drugs is a major problem associated with these well-known therapeutics' agents; moreover, the safety of some of these agents in pregnant women and fetuses is not well defined [
 <xref ref-type="bibr" rid="CR9">9</xref>].
</p>
